255 results on '"Demeule, Michel"'
Search Results
2. Sudocetaxel Zendusortide (TH1902) triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing
3. Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties
4. Sudocetaxel Zendusortide (TH1902) triggers the cGAS/ STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing.
5. Abstract 3942: Differential expression of a novel transport receptor, SORT1 (sortilin), in cancer versus healthy tissues that can be utilized for targeted delivery of anti-cancer drugs
6. Abstract 4493: Sudocetaxel Zendusortide (TH1902), a peptide-drug conjugate for the treatment of sortilin-positive (SORT1+) TNBC and Her2-positive breast cancers
7. Abstract 4499: The peptide-drug conjugate sudocetaxel zendusortide (TH1902) potentiates anti-tumoral activity of the anti-PD-L1 checkpoint inhibitor and induces immune cell infiltration in a B16-F10 syngeneic melanoma model
8. Data from ANG4043, a Novel Brain-Penetrant Peptide–mAb Conjugate, Is Efficacious against HER2-Positive Intracranial Tumors in Mice
9. Supplemental Figure 3 from ANG4043, a Novel Brain-Penetrant Peptide–mAb Conjugate, Is Efficacious against HER2-Positive Intracranial Tumors in Mice
10. Supplemental Figure 2 from ANG4043, a Novel Brain-Penetrant Peptide–mAb Conjugate, Is Efficacious against HER2-Positive Intracranial Tumors in Mice
11. Supplemental Figure 1 from ANG4043, a Novel Brain-Penetrant Peptide–mAb Conjugate, Is Efficacious against HER2-Positive Intracranial Tumors in Mice
12. Supplemental Figure Legends from ANG4043, a Novel Brain-Penetrant Peptide–mAb Conjugate, Is Efficacious against HER2-Positive Intracranial Tumors in Mice
13. Supplemental Figure 4 from ANG4043, a Novel Brain-Penetrant Peptide–mAb Conjugate, Is Efficacious against HER2-Positive Intracranial Tumors in Mice
14. The TH1902 Docetaxel Peptide-Drug Conjugate Inhibits Xenografts Growth of Human SORT1-Positive Ovarian and Triple-Negative Breast Cancer Stem-like Cells
15. Abstract 1079: Anti-cancer efficacy of TH1902, a SORT1 docetaxel peptide-drug conjugate, against ovarian and endometrial cancers xenografts alone or in combination with carboplatin
16. Abstract 1076: The peptide-drug conjugate TH1902 inhibits growth of subcutaneous melanoma xenografts and formation of lung metastases in a syngeneic mouse model
17. Abstract 1853: TH1902, a SORT1 docetaxel peptide-drug conjugate, inhibits tumor growth of human cancer stem-like cells (CD133+) from both triple-negative breast cancers and ovarian cancers
18. The Peptide-Drug Conjugate TH1902: A New Sortilin Receptor-Mediated Cancer Therapeutic against Ovarian and Endometrial Cancers
19. The Strongest Expression of P-Glycoprotein is in the Blood-Brain Barrier
20. New Peptide-Drug Conjugates for Precise Targeting of SORT1-Mediated Vasculogenic Mimicry in the Tumor Microenvironment of TNBC-Derived MDA-MB-231 Breast and Ovarian ES-2 Clear Cell Carcinoma Cells
21. TH1902, a new docetaxel‐peptide conjugate for the treatment of sortilin‐positive triple‐negative breast cancer
22. Abstract 1313: TH1902, a docetaxel peptide-drug conjugate, shows pre-clinical efficacy in several Sortilin-positive (SORT1+) cancers
23. Abstract 1439: Increasing potency of anticancer drugs through SORT1+ technology: A new targeted approach for the treatment of ovarian and endometrial cancers
24. Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin
25. Brain endothelial cells as pharmacological targets in brain tumors
26. The Antiangiogenic Agent Neovastat (Æ-941) Stimulates Tissue Plasminogen Activator Activity
27. Modulation of matrix gelatinases and metalloproteinase-activating process in acute kidney rejection
28. The antiangiogenic agent Neovastat (AE-941) stimulates tissue plasminogen activator activity
29. Multidrug Resistance in Brain Tumors: Roles of the Blood–brain Barrier
30. Abstract 685: Sortilin receptor-mediated novel cancer therapy: A targeted approach to inhibit vasculogenic mimicry in ovarian and breast cancers
31. Abstract 2910: A novel Sortilin-targeted docetaxel peptide conjugate (TH1902), for the treatment of Sortilin-positive (SORT1+) triple-negative breast cancer
32. Abstract 1061: Increasing potency of anticancer drugs through Sortilin receptor-mediated cancer therapy: A new targeted approach for the treatment of ovarian cancer
33. Abstract 6362: TH1901, a novel curcumin-peptide conjugate for the treatment of Sortilin-positive (SORT1+) cancer
34. Use of a Noninvasive Brain-Penetrating Peptide-Drug Conjugate Strategy to Improve the Delivery of Opioid Pain Relief Medications to the Brain
35. Abstract P3-10-07: Receptor-mediated chemotherapy using a new Docetaxel-peptide conjugate for Sortilin-positive triple-negative breast cancer
36. The Blood-Brain Barrier: Roles of the Multidrug Resistance Transporter P-Glycoprotein
37. Transport characteristics of a novel peptide platform for CNS therapeutics
38. Curcumin inhibits tumor growth and angiogenesis in glioblastoma xenografts
39. Inhibition of melanoma brain metastasis by targeting melanotransferrin at the cell surface
40. Identification of the cyclosporin-binding site in P-glycoprotein
41. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector Angiopep-2
42. Inhibition of tumor growth by a truncated and soluble form of melanotransferrin
43. Plasminogen-dependent internalization of soluble melanotransferrin involves the low-density lipoprotein receptor-related protein and annexin II
44. Modulation of p-glycoprotein function by caveolin-1 phosphorylation
45. Modulation of P-glycoprotein function by sphingosine kinase-1 in brain endothelial cells
46. In vivo inhibition of angiogenesis by a soluble form of melanotransferrin
47. Stimulation of cell surface plasminogen activation by membrane-bound melanotransferrin: A key phenomenon for cell invasion
48. P-glycoprotein in blood–brain barrier endothelial cells: interaction and oligomerization with caveolins
49. Differences in multidrug resistance phenotype and matrix metalloproteinases activity between endothelial cells from normal brain and glioma
50. High transcytosis of melanotransferrin (P97) across the blood–brain barrier
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.